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Abstract
Background: The purpose of this study was to review patient characteristics and evaluate the potential factors
affecting prognosis in cases of brain metastasis (BM) from colorectal cancer (CRC).
Methods: We retrospectively reviewed 93 cases of BM from CRC in our hospital. Patient demographics, neurologic
symptoms, and location and number of BMs were recorded. Factors analyzed included: age; sex; Karnofsky
performance score; number of BMs; presence of extracranial metastases; dimensions; location of tumors;
treatment modalities.
Results: The overall 1- and 2-year survival rates were 27.7 and 9.9 %. On multivariate analysis, the number of BMs,
extracranial metastases and the initial treatment modalities were found to be independent prognostic factors for
overall survival. Patients treated with surgical resection followed by WBRT or SRS had an improved prognosis
relative to those treated with surgery alone (P = 0.02 and P = 0.02, respectively). No significance difference in
survival rate was found between patients treated with SRS alone or SRS plus WBRT (P = 0.11).
Conclusions: Surgical resection of BMs from CRC in selected patients may help prolong survival. Additional
radiotherapy following surgery is valuable in improving prognosis. Extracranial metastasis, multiple BM lesions
and initial non operation can be considered as independent factors associated with poor prognosis.
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Background
Colorectal cancer (CRC) is the second-leading cause of
cancer-related deaths after lung cancer [1]. Morbidity
associated with CRC continues to increase as a result of
the expanding use of CRC screening, improved diagnos-
tic techniques, and the development of multidisciplinary
management [2]. Approximately 50 % of CRC patients
will die of metastatic disease [3]. In CRC cases, the inci-
dence of brain metastasis (BM) is much lower than at
other common metastatic sites such as the lung, liver,
and peritoneal cavity; BM accounts for only 2–3 % of
cases with pathological diagnosis at autopsy or using
surgical resection [4]. As a result of longer survival times
owing to the improved therapeutic response of the
primary tumor, the incidence of BMs may be expected
to increase. Defined as a terminal-stage phenomenon,
the prognosis of BM remains pessimistic with a median
survival time of 1–4 months [5, 6]. Alternative approaches
in treating BM such as surgical resection of the metastatic
site, stereotactic radiosurgery (SRS), and whole brain
radiation therapy (WBRT) have been used.
The present study was conducted to analyze the clin-
ical characteristics and outcomes of treatment modalities
in patients with BM from CRC, to identify independent
prognostic factors, and to provide information on related
clinical experience of treatment.
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Between 2001 and 2011, patients diagnosed with BM
from CRC at the Huashan Hospital (Shanghai, China)
were included in this study. Data were obtained using
the medical records system. Patients included in the study
had to have undergone radical resection of the primary
tumor. Pathological reports regarding primary CRC were
confirmed. BM was diagnosed by means of autopsy
reports and surgical pathology, or by clinical diagnosis.
Relevant information was reviewed with respect to the
following factors: i) patient demographics (age, sex, date
of diagnosis, Karnofsky performance score [KPS], location
of primary tumor, and stage of primary tumor); ii) BM
characteristics (date of BM diagnosis, BM location, num-
ber of BM sites, primary neurologic symptoms, and type
of treatment for BM); and iii) extracranial metastasis site
and number of treatments. Patients were followed up at
outpatient clinics, in addition to phone calls, mail, and
e-mails. Written informed consent was obtained from
all patients or their guardians. This study was ap-
proved by the ethics committee of Huashan Hospital
of Fudan University.
Treatment
Treatment modalities included surgical resection, SRS,
and WBRT. The treatment program was designed
according to the number and location of BMs, the
presence of extracranial metastases, and the patient’s
general condition.
Statistical analysis
Statistical analysis was performed using the SPSS 19.0
statistical software package (SPSS Inc., Chicago, IL,
USA). The Chi-square test was used to analyze group
comparisons where appropriate. Overall survival (OS)
was set from the day of BM diagnosis to the termination
of the records (day of death or last follow-up date). OS
was analyzed using the Kaplan–Meier method and eval-
uated by means of the log-rank test. Assessment of the
individual factors impacting on survival was accom-
plished using the log-rank test with a significance level
of P = 0.05. The Cox proportional-hazards model was




Ninety-three patients were identified in this study,
including 57 men and 36 women. The median patient
age at diagnosis of BM from CRC was 56 years. The
primary location of CRC was the colon in 44 patients
and the rectum in 49 (Table 1). The characteristics of
BM are summarized in Table 2, including the primary
neurologic symptoms, KPS, number of BMs, and loca-
tion of BM. A total of 37 (39.8 %) patients had a solitary
BM lesion while the other 56 (60.2 %) had multiple
lesions. Extracranial metastasis was detected in 57
(61.3 %) patients, including lung in 57 (61.3 %), liver in
Table 1 Patient demographics
Characteristic Patients, n (%)
Gender
Male 57, (61.3 %)
Female 36, (38.7 %)
Age
<60 50, (53.8 %)
≥60 43, (46.2 %)
Primary tumor site
Ascending colon 11, (11.8 %)
Transverse colon 3, (3.2 %)
Descending colon 7, (7.5 %)
Sigmoid colon 23, (24.7 %)
Rectum 49, (52.8 %)
Table 2 Characteristics of BM from CRC
Characteristic Patients, n (%)
Primary neurologic symptom of BM
Symptom of ICP (headache, nausea)a 43, (46.2 %)
Difficulties of balance, gait or speech 48, (51.6 %)
Asymptomatic 2, (2.2 %)
KPS
>70 33, (35.5 %)
60 ~ 70 42, (45.2 %)
<60 18, (19.3 %)
Number of BM
1 37, (39.8 %)
2 6, (6.5 %)
3 2, (2.1 %)
≥4 48, (51.6 %)
Location of solitary BM
Frontal lobe 12, (32.4 %)
Temporosphenoid lobe 4, (10.8 %)
Occipital lobe 2, (5.4 %)
Parietal lobe 3, (8.1 %)
Cerebellum 15, (40.6 %)
Others 1, (2.7 %)
Location of multiple BM
Supratentorial 25, (44.7 %)
Infratentorial 11, (19.6 %)
Supratentorial + Infratentorial 20, (35.7 %)
aICP increased intracranial pressure
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17 (18.3 %), and bone in 12 (12.9 %). Lung metastasis
was observed in every patient apart from those who only
had BM in this study. Twenty-nine patients had multiple
extracranial metastatic sites (17 with lung plus liver and
12 with lung plus bone) (Table 3).
Therapy
The treatments received by patients were as follows:
surgery only, 25 (26.9 %); SRS only, 9 (9.7 %); WBRT
only, 22 (23.7 %); surgery plus WBRT, 19 (20.4 %);
surgery plus SRS, 11 (11.8 %); and SRS plus WBRT, 7
(7.5 %). Twenty-seven patients underwent SRS during
their treatment course, nine underwent SRS as their
primary treatment for BM, and 18 underwent SRS as
salvage therapy. The prescription dose ranged from 1200
centigray (cGy) to 2400 cGy. Forty-eight patients re-
ceived WBRT during their management; in 22 of these
patients WBRT was the primary treatment and in the
other 26 WBRT was used as salvage therapy. Patients
generally received 3000 cGy in ten fractions (patients
with a KPS < 70) or 4000 cGy in 20 fractions (patients
with a KPS ≥70).
Outcomes and prognostic factors
The median survival time after the diagnosis of BM from
CRC for all 93 patients was 9.6 months. According to
the follow-up data, the overall 1- and 2-year survival
rates were 27.7 and 9.9 %, respectively (Fig. 1). Using the
log-rank test, the following factors were found to be sig-
nificant univariate predictors of survival: number of BMs
(P < 0.01), presence of extracranial metastasis (P < 0.01),
and the initial treatment modalities (P < 0.01) (Table 4).
When evaluated using multivariate analysis, the number
of BMs, presence of extracranial metastasis and the ini-
tial treatment modalities were proved to be independent
prognostic factors regarding the overall survival of
patients with BM from CRC (Table 5).
Significant differences concerning patient prognosis
were evident between the treatment modalities (Figs. 2,
3 and 4). Surgery combined with adjuvant radiotherapy
achieved higher OS times than surgery alone (surgery vs
surgery plus SRS, P = 0.02; surgery vs surgery plus WBRT,
P = 0.02). For patients who received SRS, additional
WBRT did not achieve a therapeutic advantage (SRS vs
SRS plus WBRT, P = 0.11).
Discussion
BM from primary tumors in the colon and rectum is
relatively rare as compared with BM from other sites
such as the lung and breast [7]. CRC is the most common
primary lesion among BMs originating from tumors in the
gastrointestinal tract; indeed, a recent systematic review
found that 79.9 % (2028/2538) of BMs originated from
tumors in the gastrointestinal tract [8]. BM occurs among
approximately 10 % of CRC patients during a subsequent
course of CRC, and in 2–3 % of patients BM was the first
clinical manifestation [9, 10]. Viewed as a terminal stage
of cancer, BM from CRC is associated with poor prognosis
with an OS time of <6 months [11, 12]. Development in
surgical technique and chemoradiotherapy has improved
the control of primary CRC, and has extended OS time.
These improvements have increased the chances of CRC
patients who had previously died from extracranial
systematic disease of developing BM. In addition, growth
in the use of imaging techniques has resulted in increased
detection of previously occult BM lesions. Although
tumor recurrence and extracranial metastases remain the
leading cause of death in CRC patients, BM has a growing
status due to better prognosis of CRC patients.
Lung metastases in CRC are less common than liver
metastases in CRC. However, in association with BM,
lung metastases are reportedly more commonly seen.
This concurred with the findings in our series. In previous
studies, the incidence of combined lung metastases has
been reported to range from 55 to 85 % [13, 14]; it was
Table 3 Extracranial metastatic burden
Characteristic Patients, n (%)
Extracranial metastatic site
Absent 36, (38.7 %)
Lung 57, (61.3 %)
Liver 17, (18.3 %)
Bone 12, (12.9 %)
Metastatic burden
BM/absent 36, (38.7 %)
BM/lung 28, (30.1 %)
BM/lung/liver 17, (18.3 %)
BM/lung/bone 12, (12.9 %)
Fig. 1 Survival curve for patients diagnosed as BM from CRC. Overall
survival in the 93 patients after diagnosis of BM from CRC. The
overall 1- and 2-year survival rates were 27.7 and 9.9 %, respectively
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61.3 % in the present study. Cascino and colleagues specif-
ically listed the following three pathways as potential
routes of BM through circulation [4]: (1) From the rectal
venous plexus to the inferior vena cava, (2) Through the
Batson spinal venous plexus, (3) Through the portal vein,
liver, and lung. The risk of subsequent metastasis to the
brain increases once CRC cells metastasize to the lung
and liver. This suggests that metastasis through the portal
vein and subsequently through the liver and lungs could
be the major route for BM from CRC [9]. The mechanism
associated with the development of BM remains contro-
versial with several molecular pathways and markers
under suspicion [2, 15–17].
In the current study, 72 (77.4 %) cases of BM were
found to have originated from the sigmoid colon or
rectum. A similar distribution was also observed in sev-
eral studies from different centers, with approximately
60 % of BM occurring in CRC cases [18, 19]. Some
researchers have hypothesized that tumors located in the
rectal site have a higher incidence of lung metastases
Table 5 Multivariate predictors of survival of BM (screened from
univariate predictors with P < 0.05)
Multivariate analysis
Variables Relative risk 95 % CIa P
Number of BM 0.489 −3.43 ~ 4.56 0.01
Extracranial metastasis 1.418 0.77-2.52 0.03
First treatment 5.471 1.48 ~ 9.45 <0.01
aCI confidence interval
Fig. 2 Survival curves for surgery alone versus surgery plus SRS
treatment modalities for BM. Kaplan–Meier survival curves for
patients stratified by treatment modality for BM (surgery alone
versus surgery plus SRS). There was a significant correlation between
surgery alone and surgery plus SRS (P = 0.02, log-rank test)
Table 4 Univariate predictors of survival in patients with BM
from CRC
Variables Number Median (months) χ2 P
Age
<60 50 14 3.626 0.06
≥60 43 9
Gender
Male 57 9 1.124 0.29
Female 36 11
KPS
≥70 33 13 2.168 0.14
<70 60 9
Number of BM
Solitary 37 10 11.395 <0.01
Multiple 56 6
Greatest tumor dimension, cm
>3 cm 58 10 0.117 0.73
≤3 cm 35 9
Location of BM







Yes 57 7 19.211 <0.01
No 36 13
First treatment
Surgery 55 15 38.206 <0.01
SRS 22 10
WBRT 16 6
Fig. 3 Survival curves for surgery alone versus surgery plus WBRT
treatment modalities for BM. Kaplan–Meier survival curves for patients
stratified by treatment modality for BM (surgery alone versus surgery
plus WBRT). There was a significant correlation between surgery alone
and surgery plus WBRT (P = 0.02, log-rank test)
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because of differences in vascular anatomy [20].
Hammoud et al. [21] analyzed 150 patients with BM
from CRC and found that proximal colonic lesions were
more often associated with liver metastasis, which re-
sulted in shorter survival times as compared with distal
lesions. This finding suggested that most CRC patients
with proximal colonic lesions die from extracranial me-
tastasis before BM develops. Patients with distal colon
cancer have a greater chance of developing BM before
cancer-related death [11].
In the present study, the number of BM lesions was
revealed to be an independent factor affecting patient
prognosis, which was similar to the finding of previous
studies [6, 22]. Several studies have reported that surgi-
cal resection is the most efficacious and expeditious
treatment for BM from CRC, and improvement in prog-
nosis has been found [18, 23]. Patients with multiple
sites of BM have a lower chance of undergoing brain
surgery, in consideration of the surgical difficulty and
potential complications. In addition, poor systemic status
is more common in this group of patients, which may
affect the more palliative treatment strategies. In our
study, radiotherapy, WBRT, or SRS, followed by surgical
resection led to significantly improved survival relative to
surgery alone. This study has found significant improved
survival with surgical resection. This may reflect a selec-
tion bias, as patients with limited systemic metastatic load,
solitary brain lesions in surgically accessible areas, and/or
a life expectancy of 6 months or greater are more likely to
be selected for curative resection. On the other hand, it
highlights the possibility that brain metastases, if treated
aggressively, can lead to improved survival.
WBRT or SRS alone are considered as palliative treat-
ments for relieving the neurological symptoms of patients
who are unfit for surgery. In the present study, selection
bias was obviously a matter of prime importance. Patients
with multiple BM lesions were more suitable for receiving
WBRT than SRS. Patients with increased numbers of BM
lesions have been proved to have shorter survival times,
and this may explain the difference in the outcomes
of the radiotherapies. SRS followed by additional
WBRT exhibited no advantage over SRS alone in the
current study; this was also noted by Schoeggl et al.
[24]. Whether the treatment option will provide benefit
over other treatment strategies, should be verified in
prospective studies.
Conclusions
BM remains a terminal-stage phenomenon of CRC. The
findings of the present study indicated that surgical re-
section of BM in selected patients may prolong survival.
Additional radiotherapy following surgery is valuable
in providing additional improvement in prognosis.
Combined extracranial metastasis, more than three
BM lesions and the initial no operation are considered
independent factors associated with poor prognosis.
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